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Purpose
This study was undertaken to evaluate the significance of cyclooxygenase-2 (COX2) over-
expression and the expression of somatostatin receptor (SSTR) subtypes in gastroentero-
pancreatic neuroendocrine tumors (GEP-NETs). 
Materials and Methods
Twohundred and forty-seven cases of GEP-NET, comprising 86 foregut and 156 hindgut primary
NETs, and 5 metastatic NETs in the liver, were studied retrospectively with immunohisto-
chemistry for COX2, chromogranin A, Ki-67, SSTR1, SSTR2, and SSTR5.
Results
COX2 overexpression was observed in 54%(126 of 234), and SSTR1, SSTR2, and SSTR5 positivity
in 84%(196 of 233), 72%(168 of 233), and 55%(128 of 232), respectively. COX2 overexpression
was found to be positively correlated with Ki-67 labeling index and inversely correlated with
the expression of SSTR subtypes. In addition, the expression of SSTR subtypes was tightly
correlated in any comparative pairs. A significant inverse correlation was found between COX2
and SSTR2 expression in the foregut, but not hindgut NETs. Kaplan-Meier analyses showed that
COX2 overexpression (p=0.003) and high Ki-67 labeling index (pģ0.001) were associated with
poor overall survival (OS), whereas expression of SSTR2 (pģ0.001) was associated with better OS
of GEP-NET patients. Multivariate analysis revealed negative SSTR2 expression as an
independent prognostic marker in GEP-NET patients (pģ0.001). 
Conclusion
Our results suggest that expression of SSTR subtypes is associated with favorable prognosis,
whereas COX2 overexpression is associated with poor prognosis in GEP-NETs. Taken together,
COX2 could be a possible therapeutic target in some subsets of GEP-NETs. 
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Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) con-
stitute a heterogeneous group of tumors that originate from the neu-
roendocrine cell system, have widely divergent clinical presentations
and are relatively infrequent, constituting only approximately 2% of
all neoplasms; they are typically indolent, slow-growing tumors [1].
GEP-NETs occur in approximately 1.95-2.50 per 100,000 population
and pancreatic endocrine tumors occur in approximately 1 per 100,000
population and represent 1-2% of all pancreatic neoplasms [2].
Cyclooxygenase-2 (COX2) is expressed in neuroendocrine cells
of human colonic mucosa [3], and in cell lines derived from NETs,
including metastatic carcinoids of the pancreas. The neuroendocrine
tumor cells express COX2, and furthermore, their growth is inhibited
by non-steroidal anti-inflammatory drugs (non-steroidal anti-inflam-
matory drugs or COX2 selective inhibitors) [4]. A few reports have
found that COX2 expression was associated with poor prognosis of
midgut carcinoid tumors or reported high COX2 expression in the
advancing edge of gastrointestinal carcinoid tumors [5]. Ohike and
Morohoshi [6] reported that the distribution of COX2-positive cells
tended to be similar to the distribution of Ki-67-positive cells in pan-
creatic NETs, and that there was a close relationship between COX2
expression and tumor proliferative activity. 
The small cyclic peptide hormone somatostatin is present in the
human body in 2 molecular forms, i.e., somatostatin-14 (consistingof 14 amino acids) and somatostatin-28 (28 amino acids). It exerts
diverse biologic effects through interaction with specific somatostatin
receptors (SSTRs) located in target tissues. SSTRs are a family of 5
widely distributed G protein-coupled receptors, including subtypes
SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5, which characteristi-
cally consist of a single polypeptide chain with 7 transmembrane-
spanning domains, extracellular domains with ligand binding sites
and intracellular domains with sites linked to the activation of second
messengers. SSTRs mediate different intracellular signaling pathways
involved in cell proliferation, differentiation, and angiogenesis [7]. 
The inhibitory effects of either somatostatin or its analogs, mediated
via SSTRs, are linked with several intracellular systems, i.e., inhibition
of adenylyl cyclase, resulting in a decrease in intracellular cyclic AMP
levels; reduction of Ca
2+ influxes, resulting in reduced intracellular
Ca
2+ levels; and, in a number of tissues, stimulation of tyrosine
phosphatase activity. Long-acting somatostatin analogs have been
used for more than 10 years to treat endocrine tumors. Their high
receptor-binding affinity is the basis for both diagnostic uses, like
scintigraphy or positron emission tomography scans, and therapeutic
procedures [8]. A large variety of primary tumors and their metastases
can express a high density of SSTRs. Pituitary tumors, endocrine
pancreatic tumors and carcinoids express multiple SSTR subtypes,
but SSTR2 predominance was found in 90% of carcinoids and 80%
of endocrine pancreatic tumors. It has been recently shown that
treatment of non-functioning pancreatic endocrine tumor with the
somatostatin analog octreotide can stabilize the disease in approxi-
mately 40% of cases [9,10].
To study the clinical significance of the expression of COX2 and
SSTR subtypes in GEP-NETs, we analyzed immunostaining findings
for COX2 and SSTR subtypes in 247 patients with GEP-NET.
Materials and Methods
1   Patients
The formalin-fixed and paraffin-embedded tumor tissues of patients
treated from 1989 to 2008 were retrieved from the archives at the
Department of Pathology at Seoul National University Hospitals in
Seoul and Bundang, Korea. The inclusion criteria were primary or
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Total Foregut Hindgut Liver metastasis p-value
Gender Female 97 (39) 34 (40) 62 (40) 1 (20) 0.672
Male 150 (61) 52 (60) 94 (60) 4 (80)
Treatment Endoscopic biopsy 155 (63) 27 (31) 128 (82) 0 (0) ģ0.001
Surgical resection 92 (37) 59 (69) 28 (18) 5 (100)
Stage Confined within organ 225 (92) 76 (89) 149 (96) 0 (0) ģ0.001
Invasion of adjacent organ 8 (3) 6 (7) 2 (1) 0 (0)
Distant metastasis 13 (5) 3 (4) 5 (3) 5 (100)
Synchronous cancer Absent  223 (90) 67 (78) 151 (97) 5 (100) ģ0.001
Present 24 (10) 19 (22) 5 (3) 0 (0)
Histology WDNET 181 (73) 49 (57) 132 (85) 0 (0) ģ0.001
WDNEC 31 (13) 17 (20) 10 (6) 4 (80)
PDNEC 17 (7) 7 (8) 9 (6) 1 (20)
Mixed exo- and endocrine carcinoma 18 (7) 13 (15) 5 (3) 0 (0)
Mitoses (per 10 HPF) 0-1 32 (13) 11 (13) 21 (13) 0 (0) 0.272
2-20 2 (1) 2 (2) 0 (0) 0 (0)
ĥ20 4 (2) 3 (4) 1 (1) 0 (0)
Unknown 209 (34) 70 (81) 134 (86) 5 (100)
Lymphatic invasion Negative 207 (84) 64 (74) 139 (89) 4 (80) 0.012
Positive 40 (16) 22 (26) 17 (11) 1 (20)
Vascular invasion Negative 216 (87) 71 (83) 142 (91) 3 (60) 0.028
Positive 31 (13) 15 (17) 14 (9) 2 (40)
Lymph node metastasis Negative 45 (52) 36 (63) 6 (22) 3 (100) 0.001
Positive 42 (48) 21 (37) 21 (78) 0 (0)
Follow-up Alive 162 (66) 44 (51) 116 (74) 2 (40) ģ0.001
Dead 32 (13) 22 (26) 8 (5) 2 (40)
Unknown 53 (21) 20 (23) 32 (21) 1 (20)
Table 1. Clinicopathologic features of gastroenteropancreatic neuroendocrine tumors
Values are presented as number (%). WDNET, well-differentiated neuroendocrine tumor; WDNEC, well-differentiated neuroendocrine carcinoma; PDNEC, poorly differentiated
neuroendocrine carcinoma; HPF, high power field.Hee Sung Kim, et al_COX2 Overexpression in Neuroendocrine Tumors
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metastatic GEP-NET diagnosed by endoscopic biopsy and surgical
resection, and the exclusion criteria were neuroendocrine tumor of
appendiceal origin or metastatic neuroendocrine tumor of unknown
primary origin.
Two hundred and forty-seven patients (mean age, 53 years; range,
21 to 88 years) were included in this study. Among them, follow-up
and survival information was obtained for 194 patients. The mean
follow-up period was 44 months (range, 1 to 140 months), as of
September 2010. The study protocol was approved by the Institu-
tional Review Board committee of Seoul National University Hospital
(C-1012-027-343). Patient survival data, including dates and causes
of death, were obtained from the Korean Central Cancer Registry at
the Ministry of Health and Welfare. Standard histopathological
examinations included assessment of the pathological tumor stage,
according to the criteria described in the 6th edition of the American
Joint Committee on Cancer staging manual [11]. Histologic classi-
fications were performed as recommended by the World Health Or-
ganization (WHO) guidelines [12]. 
SSTR1
SSTR2
SSTR5
COX2
Ki-67
Fig. 1. Immunostaining results of gastroenteropancreatic neuroendocrine tumors for cyclooxygenase-2 (COX2), Ki-67, and somatostatin
receptors (SSTRs) 1, 2, and 5. In neuroendocrine tumors, COX2 and SSTR5 are localized in the cytoplasm, Ki-67 and SSTR1 are in the nuclei,
and SSTR2 is in the membrane. First column, negative; second column, moderate positive; third column, strong positive; fourth column, high
power field of strong positive (immunohistochemical staining with DAB, first three columns,200; fourth column,400).Cancer Res Treat. 2011;43(3):181-188
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2 Tissue array preparation
Tissues obtained from patients were routinely fixed in 10% buffered
formalin and embedded in paraffin blocks. After screening the
available slides for each case, we selected a paraffin block that was
well fixed and contained a representative section of the tumor. One
tissue column (2.0 mm in diameter) was obtained from each selected
paraffin block and arranged in separate new paraffin blocks with 60
holes, using a trephine apparatus (Superbiochips Laboratories, Seoul,
Korea). Thus, tissue array blocks containing tumor tissues (2 mm in
diameter) were produced from all samples. Microarray blocks were
then sectioned at 4 Ǻ m and processed for immunohistochemical
staining. After removing paraffin with xylene, the sections were
rehydrated with graded ethanol and immersed in Tris-buffered saline.
3   Immunohistochemistry
Immunostainings for COX2, Ki-67, chromogranin A (CgA), SSTR1,
SSTR2, and SSTR5 were performed using Bond Polymer Refine
Detection kits (Leica Microsytems, Newcastle Upon Tyne, UK) and
Leica BOND-MAX autostainer (Leica Microsystems) with the
following antibodies: COX2 (1 : 100, CX229, mouse monoclonal,
Cayman Chemical, Ann Arbor, MI), Ki-67 (1 : 100, MIB-1, mouse
monoclonal, DAKO, Carpentaria, CA), CgA (1 : 100, M0869, mouse
monoclonal, DAKO), SSTR1 (1 : 100, ab2366, rabbit polyclonal,
Abcam, Cambridge, UK), SSTR2 (1 : 100, MAB4224, mouse
monoclonal, R&D systems, Minneapolis, MN), and SSTR5 (1 : 100,
PAB0299, rabbit polyclonal, Abnova, Jhongli, Taoyuan, Taiwan), res-
pectively. 
Immunoreactivity for COX2 was evaluated in tumor cells using a
semi-quantitative system, based on the sum of staining intensity
(0=negative staining, 1=weak, 2=intermediate, 3=strong staining) and
positive cell percentage scores (0=0%, 1=1-25%, 2=26-50%, 350%).
Thus, scores from 0-3 assigned for staining intensity and percentage
scores were added to obtain an overall score (maximum 6). With
regard to COX2 staining, scores of 0-4 (negative or low expression)
were considered negative and scores of 5-6 (high expression) as
positive [5,13]. For CgA, samples displaying any nuclear staining in
tumor cells were scored as positive; for SSTR1, samples showing any
cytoplasm or nuclear staining were scored as positive; for SSTR2,
samples showing membranous staining inĥ50% of tumor cells with
moderate staining were scored as positive; finally, for SSTR5, samples
displaying cytoplasmic staining inĥ50% tumor cells were scored as
positive. Ki-67 staining was performed in all 247 patients on tissue
array and grade was obtained in 232 patients. The number of cells
that stained for Ki-67 were expressed as percentages; thus, the Ki-67
labeling index was graded as G1 if the number of positive cells was
2%, G2 when 3-20%, and G3 whenĥ20%. 
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4 Statistical analyses
Spearman’s rank correlation was performed for analyses of 6 protein
expressions in GEP-NETs. Survival rates were calculated using the
Kaplan-Meier method, and groups were compared using the log rank
test. Kaplan-Meier curves were plotted using overall survival (OS)
data. p-valuesģ0.05 were considered statistically significant. Multi-
variate analyses were conducted using the Cox proportional hazard
regression model. Factors included in the multivariate analysis for OS
were pathologic stage (confined within organ vs. advanced stage),
histology (well-differentiated NET or well-differentiated neuroen-
docrine carcinoma vs. poorly differentiated neuroendocrine carcinoma
or mixed type), lymphatic invasion (negative vs. positive), Ki-67
labeling index (G1 vs. G2 or G3), COX2 (no overexpression vs. over-
expression), and SSTR2 (positive vs. negative). Statistical analysis was
performed using the SPSS ver. 15.0 (SPSS Inc., Chicago, IL).
Results
1   Clinicopathologic profiles of GEP-NET patients
Patient characteristics by tumor site are summarized in Table 1.
Tumor sites of NET in those patients were, as follows: 86 foregut
(49 stomach, 29 duodenum, 8 pancreas), 156 hindgut (18 colon, 138
rectum), and 5 metastatic tumors in the liver (3 colon primary, 2
pancreas primary). Two hundred and twenty-five (91%) of 247
tumors were confined within an organ, and 21 (9%) tumors were in an
advanced stage: 9 foregut, 7 hindgut primary tumors, and 5 liver
metastatic tumors. Synchronous cancer was associated in 19 (22%)
foregut and 5 (3%) hindgut primary tumors. Histologically poor
differentiation was observed in 20 (23%) foregut tumors, 14 (9%)
hindgut primary tumors, and 1 (20%) metastatic liver tumor. The
proportion of patient death was significantly higher in foregut patients
than in hindgut patients (33% [22 of 66] vs. 5% [8 of 123], pģ0.001). 
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Fig. 2. Kaplan-Meier analyses of overall survival in 194 patients
with gastroenteropancreatic neuroendocrine tumors. (A) Cyclooxy-
genase-2: solid line, no overexpression; dotted line, overexpression.
(B) Ki-67: solid line, G1; dotted line, G2 or G3. (C) Somatostatin
receptor 2: solid line, positive; dotted line, negative.Cancer Res Treat. 2011;43(3):181-188
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No. Hazard ratio 95% CI p-value
Stage Confined within organ 163
Advanced stage 19 4.836 1.997-11.710 ģ0.001
Histology WDNET or WDNEC 156
PDNEC or Mixed type 26 0.733 0.275-1.952 0.534
Lymphatic invasion Negative 151
Positive 31 2.681 0.975-7.371 0.056
Ki-67 G1 116
G2 or G3 66 2.863 1.096-7.476 0.032
COX2 overexpression No 73
Yes 109 1.046 0.337-3.248 0.937
SSTR2 Positive 131
Negative 51 6.565 2.412-17.872 ģ0.001
Table 3. Multivariate analysis for overall survival in gastroenteropancreatic neuroendocrine tumors
CI, confidence interval; WDNET, well-differentiated neuroendocrine tumor; WDNEC, well-differentiated neuroendocrine carcinoma; PDNEC, poorly differentiated neuroendocrine
carcinoma; COX2, cyclooxygenase-2; SSTR, somatostatin receptor.
2 Results of immunostaining in GEP-NET tissues
Intracellular localization of proteins was shown, as follows: COX2
and SSTR5 in the cytoplasm, CgA, Ki-67, and SSTR1 in the nuclei,
and SSTR2 in the membrane of tumor cells (Fig. 1). Overall, COX2
overexpression was observed in 54% (126 of 234), CgA positivity in
35% (82 of 232), SSTR1 expression in 84% (196 of 233), SSTR2
expression in 72% (168 of 233), and SSTR5 expression in 55%
(128 of 232). Ki-67 labeling index was obtainable in 232 cases and
scored as G1 in 65% (150 cases), G2 in 27% (63 cases), and G3 in
8% (19 cases). COX2 overexpression showed significant association
with poor differentiation, higher stage, and lymphatic invasion. Ki-67
labeling index was higher in foregut NETs, poorly differentiated NETs,
and NETs with lymphatic invasion. In terms of primary tumor site,
rates of CgA positivity and G2 or G3 grade Ki-67 were higher in
foregut tumors; in contrast, expression of all SSTR subtypes was
higher in hindgut tumors (Table 2).
All of SSTR1, SSTR2, and SSTR5 expression was significantly
associated with better differentiation, lower pathologic stage, and
absence of lymphatic invasion. Among the 3 SSTR subtypes, primary
site-specific difference was noted for SSTR5, which was higher in
hindgut NETs than in foregut NETs (Table 2). 
Correlation analysis in the expression of 6 proteins used in this
study was performed. Strong correlations were noted in any com-
parative pairs of SSTR1, SSTR2, or SSTR5 expression (ǿ ĥ0.3, p
ģ0.001). An inverse correlation between COX2 and SSTR2 ex-
pression was noted in foregut NETs (ǿ =-0.3, p=0.002). 
3   Survival analyses by protein expression
Kaplan-Meier analyses showed decreased mean OS for patients
with COX2 overexpression (92 months vs. 127 months, p=0.003)
and patients with G2 or G3 grades Ki-67 labeling indices (82 months
vs. 126 months, pģ0.001). In contrast, SSTR2 expression was found
to be significantly associated with better mean OS (127 months vs.
66 months, pģ0.001) (Fig. 2). SSTR1 expression (55 months vs.
120 months, pģ0.001) and SSTR5 expression (101 months vs. 118
months, p=0.003) were also associated with better mean OS. 
Multivariate regression analysis with variables including pathologic
stage, histology, Ki-67 labeling index, lymphatic invasion, COX2
overexpression, and SSTR2 expression was performed. Stage (hazard
ratio, 4.836; 95% confidence interval [CI], 1.997 to 11.710; pģ0.001),
Ki-67 labeling index (hazard ratio, 2.863; 95% CI, 1.096 to 7.476;
p=0.032), and negative SSTR2 expression were independent prog-
nostic markers in GEP-NETs (hazard ratio, 6.565; 95% CI, 2.412 to
17.872; pģ0.001); however, histologic type, presence of lymphatic
invasion, or COX2 overexpression were not independent prognostic
markers (Table 3). 
Discussion
The present series consisted of 86 (35%) foregut primary, 156
(63%) hindgut primary, and 5 (2%) liver metastatic NETs. In 225
(91%) cases, tumors were confined to an organ, and in 21 (9%) cases,
tumors were either locally advanced or metastatic. Midgut carcinoid
tumor was not included in the present study, which reflects the low
prevalence of midgut carcinoid tumors in Asia [14]. 
The presence of COX2-immunoreactive neuroendocrine cells was
observed not only in the large intestine, but also in the stomach,
duodenum, and small intestine [3]. A few authors have reported that
elevated COX2 expression was involved in the tumorigenesis of
pancreatic endocrine [6,15] and gastrointestinal carcinoid tumors [5],
and that COX inhibitors are currently being developed for chemo-
preventive purposes and as adjuvant drugs for the treatment of several
human malignancies. NET appear to be an attractive target for suchHee Sung Kim, et al_COX2 Overexpression in Neuroendocrine Tumors
therapies, because of their low proliferative capacity and relative
resistance to both chemotherapy and bio-therapeutic modalities, such
as interferon-alpha or somatostatin therapy. In a cell culture model of
COX2-expressing neuroendocrine neoplasia, they found that COX2
up-regulated the expression and bioactivity of CgA. They also
showed that the COX inhibitor sulindac had direct antiproliferative
effects on GEP-NET cell lines, as well as colon cancer cell lines [4]. 
Some links between COX2 and somatostatin, such as extra-
cellular signal-regulated protein kinase, a downstream molecule in
the mitogen-activated protein kinase pathway induced by SSTR
binding, have been reported [16]. Furthermore, rofecoxib and
octreotide were found to have synergic antineoplastic effects in vitro
in SGC-7901 cells (a gastric cancer cell line) and in xenografts in
nude mice [17], and human gastric adenocarcinoma growth was
found to be inhibited preoperatively by a combination of celecoxib
and octreotide [18]. 
The placebo-controlled, prospective randomized study group
reported that the long-acting octreotide showed substantial antitumor
effect and longer progression-free survival than placebo in patients
with well-differentiated NETs and a low tumor burden [19]. The
antineoplastic activity of somatostatin analogs has also been demon-
strated in several experimental models, both in vivo and in vitro.
Mitosis inhibition was mediated by SSTRs 2 and 5 and resulted in
cell cycle arrest [20]. Similarly, the loss of the SSTR2 expression in
some human adenocarcinomas seemed to be responsible for losing
the regulation of cell proliferation [21]. 
There are a few reports that suggest the need for indications for
somatostatin analog treatment and for predictive markers of treatment
response and somatostatin analog resistance. Slaby et al. [22] examined
the gene expression of SSTR subtypes by quantitative reverse trans-
criptase-polymerase chain reaction (RT-PCR) and the correlations
between those expression and the outcome of GEP-NET treatment
with somatostatin analogs, and found that only SSTR4 was
significantly associated with the stabilization of disease during
somatostatin analog therapy. In contrast, Toboada et al. [23] showed
that elevated tumor expression of SSTR1, SSTR2, and dopamine
receptor 2 may help improve responsiveness to somatostatin
analogs. 
SSTR expression in GEP endocrine tumors is heterogeneous. The
types most commonly detected are SSTR1 and 2, followed by SSTR3
and 5, and then by SSTR4, which is poorly represented in GEP-NETs
[24]. A correlative immunohistochemical and RT-PCR analysis
showed that SSTRs 1-5 were heterogeneously expressed in GEP
endocrine tumors and that immunohistochemistry was a reliable tool to
detect SSTRs 2, 3, and 5 in both surgical and biopsy specimens [24].
In our series, the overall positive rates of SSTRs in GEP-NETs
were 84% for SSTR1, 72% for SSTR2, and 55% for SSTR5. The
expression of all 3 subtypes was more frequently observed in well-
differentiated NETs, hindgut primary NETs, and NETs with a low
pathologic stage. Further stratified analysis in a larger series is re-
quired to examine the clinical utilization of the expression of SSTRs
in the treatment of GEP-NETs as a predictive marker for response to
somatostatin analog treatment.
The present study showed that COX2 overexpression in GEP-
NETs is associated with aggressive pathologic variables and poor OS.
In contrast, the expression of SSTR subtypes is shown to be asso-
ciated with better OS. Furthermore, inverse correlations were noted
between the expression of COX2 and SSTRs in GEP-NETs. Our
results also suggest that COX2 could be a therapeutic target in a
selected subset of GEP-NETs.
Conclusion
This study showed that COX2 overexpression is associated with
poor prognosis, whereas expressions of SSTRs 1, 2, and 5 are
associated with favorable prognosis in GEP-NETs. These results
suggest that COX2 could be considered as a possible therapeutic
target in some subsets of GEP-NETs.
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